Switch theme
Sign up to access all valuation multiples
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
1998
1.0K+
LTM Revenue $784M
LTM EBITDA -$192M
$4.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PTC Therapeutics has a last 12-month revenue of $784M and a last 12-month EBITDA of -$192M.
In the most recent fiscal year, PTC Therapeutics achieved revenue of $807M and an EBITDA of -$120M.
PTC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PTC Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $938M | $807M | XXX | XXX | XXX |
| Gross Profit | $654M | $872M | XXX | XXX | XXX |
| Gross Margin | 70% | 108% | XXX | XXX | XXX |
| EBITDA | -$330M | -$120M | XXX | XXX | XXX |
| EBITDA Margin | -35% | -15% | XXX | XXX | XXX |
| Net Profit | -$559M | -$627M | XXX | XXX | XXX |
| Net Margin | -60% | -78% | XXX | XXX | XXX |
| Net Debt | $1.0B | $1.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PTC Therapeutics's stock price is $45.
PTC Therapeutics has current market cap of $3.6B, and EV of $4.9B.
See PTC Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.9B | $3.6B | XXX | XXX | XXX | XXX | $-4.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PTC Therapeutics has market cap of $3.6B and EV of $4.9B.
PTC Therapeutics's trades at 6.2x LTM EV/Revenue multiple, and -25.5x LTM EBITDA.
Analysts estimate PTC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PTC Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.9B | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | -40.6x | XXX | XXX | XXX |
| P/E | -9.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -26.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPTC Therapeutics's NTM/LTM revenue growth is -3%
PTC Therapeutics's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, PTC Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PTC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PTC Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -64% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -18% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 66% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 111% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PTC Therapeutics acquired XXX companies to date.
Last acquisition by PTC Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . PTC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PTC Therapeutics founded? | PTC Therapeutics was founded in 1998. |
| Where is PTC Therapeutics headquartered? | PTC Therapeutics is headquartered in United States of America. |
| How many employees does PTC Therapeutics have? | As of today, PTC Therapeutics has 1.0K+ employees. |
| Who is the CEO of PTC Therapeutics? | PTC Therapeutics's CEO is Dr. Matthew B. Klein, F.A.C.S.,M.D.,M.S.. |
| Is PTC Therapeutics publicy listed? | Yes, PTC Therapeutics is a public company listed on NAS. |
| What is the stock symbol of PTC Therapeutics? | PTC Therapeutics trades under PTCT ticker. |
| When did PTC Therapeutics go public? | PTC Therapeutics went public in 2013. |
| Who are competitors of PTC Therapeutics? | Similar companies to PTC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PTC Therapeutics? | PTC Therapeutics's current market cap is $3.6B |
| What is the current revenue of PTC Therapeutics? | PTC Therapeutics's last 12-month revenue is $784M. |
| What is the current EBITDA of PTC Therapeutics? | PTC Therapeutics's last 12-month EBITDA is -$192M. |
| What is the current EV/Revenue multiple of PTC Therapeutics? | Current revenue multiple of PTC Therapeutics is 6.2x. |
| What is the current EV/EBITDA multiple of PTC Therapeutics? | Current EBITDA multiple of PTC Therapeutics is -25.5x. |
| What is the current revenue growth of PTC Therapeutics? | PTC Therapeutics revenue growth between 2023 and 2024 was -14%. |
| Is PTC Therapeutics profitable? | Yes, PTC Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
